2013年至2021年接受全髋关节置换术的高合并症负担患者的收入、成本与贡献毛利趋势
本研究回顾性分析了本机构2013年至2021年间978例接受初次择期全髋关节置换术的高合并症负担患者(Charlson合并症指数≥5且美国麻醉医师协会评分3或4分),收集人口学、围手术期数据及住院期间收入、成本和贡献毛利。结果显示直接成本显著增加(P=0.002),总收入无显著变化(P=0.486),贡献毛利降至2013年值的38.0%但未达统计学显著(P=0.222)。
要点
- 高合并症负担患者全髋关节置换术直接成本显著增加(P=0.002)
- 总收入在研究期间保持稳定(P=0.486)
- 贡献毛利降至2013年值的38.0%,但未达统计学显著(P=0.222)
核心结论
- 高合并症负担患者全髋关节置换术成本增加未获得相应收入增加,导致过去十年贡献毛利持续下降。
- 作者认为可能需要重新评估全髋关节置换术的报销模式以纳入患者的高合并症负担,以维持广泛的可及性。
研究设计与样本
- 回顾性研究,纳入本机构2013年至2021年间13439例初次择期全髋关节置换术患者中978例高合并症负担患者(Charlson合并症指数≥5且美国麻醉医师协会评分3或4分)。
- 最终分析纳入978例具有完整财务数据的高合并症负担患者,收集人口学、围手术期数据及住院期间收入、成本和贡献毛利,分析财务指标相对2013年值的变化百分比,采用线性回归确定趋势显著性。
- 证据等级为III级。
主要发现
- 2013年至2021年间,直接成本显著增加(P=0.002),总成本增加未达统计学显著(P=0.056)。
- 研究期间收入保持稳定(P=0.486)。
- 贡献毛利降至2013年值的38.0%,但未达统计学显著(P=0.222)。
- 90天并发症发生率和家庭出院率在研究期间保持稳定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the increasing utilization of total hip arthroplasty (THA) in patients who have a high comorbidity burden (HCB), coinciding with modifications to reimbursement models over the past decade, an evaluation of the financial impact of HCB on THA over time is warranted. This study aimed to investigate trends in revenue and cost associated with THA in HCB patients. METHODS: Of 13,439 patients who had primary, elective THA between 2013 and 2021 at our institution, we retrospectively reviewed 978 patients considered to have HCB (Charlson comorbidity index ≥ 5 and American Society of Anesthesiology scores 3 or 4). We collected patient demographics, perioperative data, revenue, cost, and contribution margin (CM) of the inpatient episode. We analyzed changes as a percentage of 2013 values over time for these financial markers. Linear regression determined trend significance. The final analysis included 978 HCB patients who had complete financial data. RESULTS: Between 2013 and 2021, direct costs increased significantly (P = .002), along with a nonsignificant increase in total costs (P = .056). While revenue remained steady during the study period (P = .486), the CM decreased markedly to 38.0% of 2013 values, although not statistically significant (P = .222). Rates of 90-day complications and home discharge remained steady throughout the study period. CONCLUSIONS: Increasing costs for HCB patients undergoing THA were not matched by an equivalent increase in revenue, leading to dwindling CMs throughout the past decade. Re-evaluation of reimbursement models for THA that account for patients' HCB may be necessary to preserve broad access to care. LEVEL OF EVIDENCE: III.
引用
- Ashkenazi I, Katzman J, Thomas J, et al. Trends in Revenue, Cost, and Contribution Margin of Patients Who Have a High Comorbidity Burden Undergoing Total Hip Arthroplasty From 2013 to 2021. J Arthroplasty. 2024. PMID: 38677346. doi:10.1016/j.arth.2024.04.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。